EN | UA
EN | UA

Help Support

Back

Long-term administration of natalizumab is effective and safe to treat multiple sclerosis

Neurons Neurons
Neurons Neurons

What's new?

Long-term administration of natalizumab has high effectiveness and an adequate safety profile in individuals having multiple sclerosis.

A retrospective observational study depicted that in people diagnosed with relapsing-remitting multiple sclerosis, natalizumab is effective, has an acceptable safety profile, and can be given with good tolerability for a longer period.  Investigators undertook this study to report the real-world data regarding the long-term use of natalizumab for multiple sclerosis management.

The study included 51 multiple sclerosis people (62.74% females) who underwent treatment with ≥ 24 natalizumab infusions. The mean disease duration was 9.86±0.7 years and the mean number of natalizumab infusions was 45.58±2.74. Expanded Disability Status Scale (EDSS) values, relapse rate, rate of adverse events, and type of adverse events linked with natalizumab use were assessed.

An increased number of people (80.39%) were relapse-free. Furthermore, a mild decrease in mean EDSS value was noted after natalizumab commencement in people who had not been administered other disease modifying therapies anteriorly. Increased liver transaminases (13.72%), dysmenorrhea (1 patient), and local infections (7.84%) were noted.

The rate of serious side effects was noted to be 3.92. No cases of progressive multifocal leukoencephalopathy were witnessed. Thus, the long-term administration of humanized monoclonal antibody natalizumab is effective, safe, and well-tolerated in people suffering from relapsing-remitting multiple sclerosis. However, the patients must be closely monitored, concluded the study authors.

Source:

CNS & Neurological Disorders - Drug Targets

Article:

Real-World Data Regarding Long-Term Administration of Natalizumab Derived from a Neurology Department along with Literature Review

Authors:

Eugenia Irene Davidescu et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: